Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group Blood Cancer J
Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics BRIT J HAEMATOL
Diagnosing Helicobacter pylori using autoencoders and limited annotations through anomalous staining patterns in IHC whole slide images INT J COMPUT ASS RAD
Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis THROMB HAEMOSTASIS
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial Eur J Haematol
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups CANCERS
A two-phase epigenome-wide four-way gene-smoking interaction study of overall survival for early-stage non-small cell lung cancer Mol Oncol
The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045 JNCI-J NATL CANCER I